4. Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) combines marketed medicines with development opportunities in hematology, oncology, and immunology. Second-quarter 2026 net product sales increased 14% to $67 million, while total revenue reached $78.7 million. TAVALISSE sales grew 18%, and REZLIDHIA sales increased 27%.
The attraction is an operating business that can help fund further development. Rigel reported quarterly net income of $17.3 million and raised its full-year revenue guidance to approximately $285 million–$295 million.
However, product performance was uneven. GAVRETO sales declined 10%, while cash, cash equivalents, and short-term investments fell to $95.3 million from $155 million at year-end. Prior-year earnings also benefited from a substantial noncash collaboration item, making headline profit comparisons less informative.
Ranking rationale
Existing products and profitability provide substance, although mixed sales trends and a smaller cash reserve temper its position.
